Aparna Pharmaceuticals, a leader in manufacturing Active Pharmaceutical Ingredients (APIs) and Advanced Drug Intermediates, has announced that its manufacturing facility, Aparna Organics, located in Pydibhimavaram, Srikakulalam, Andhra Pradesh, has received VAI classification from the United States Food and Drug Administration (USFDA). The USFDA audited the facility during the month of September 2023.

This achievement underscores Aparna’s unwavering commitment to quality and compliance with global regulatory requirements.

Rakesh Reddy, Managing Director, Aparna Pharmaceuticals said, “This clearance is a testament to our team’s relentless pursuit of excellence. Our facility’s compliance journey has been meticulous. We are thrilled to receive the USFDA’s stamp of approval."

With the successful completion of the FDA audit, Aparna Pharmaceuticals has emerged as a leading manufacturer of APIs and Advanced Drug Intermediates and attained global recognition by providing high quality products manufactured as per cGMP guidelines. Driven by innovative R&D and optimum utilisation of resources, the company is strongly committed to enhancing customer satisfaction and catering to the discerning needs of renowned pharmaceutical companies.

Aparna Pharmaceuticals a division of Aparna Group, which comprises of diversified business verticals including Aparna Constructions, Aparna Enterprises and Aparna Property Management Services with a group turnover of $1 Billion. In 2020, the group sought to strategically diversify its portfolio and enter the pharmaceutical API and intermediate manufacturing space with the establishment of Aparna Pharmaceuticals. The company acquired a brown field manufacturing site in Pydibhimavaram, Andhra Pradesh in 2021.